A study led by Massachusetts General Hospital (MGH) investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that
Continue reading »
Argenx Doses First Patient in Global Phase 3 Registration Trial of Efgartigimod
September 06, 2018 — Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company
Continue reading »